Literature DB >> 10754584

Effects of propranolol on the QT dispersion in congestive heart failure.

.   

Abstract

OBJECTIVE - Studies have shown that therapy with beta-blockers reduces mortality in patients with heart failure. However, there are no studies describing the effects of propranolol on the QT dispersion in this population. The objective of this study was to assess the electrophysiological profile, mainly QT dispersion, of patients with heart failure regularly using propranolol. METHODS - Fifteen patients with heart failure and using propranolol were assessed over a period of 12 months. Twelve-lead electrocardiograms (ECG) were recorded prior to the onset of beta-blocker therapy and after 3 months of drug use. RESULTS - A significant reduction in heart rate, in QT dispersion and in QTc dispersion was observed, as was also an increase in the PR interval and in the QT interval, after the use of propranolol in an average dosage of 100 mg/day. CONCLUSION - Reduction in QT dispersion in patients with heart failure using propranolol may explain the reduction in the risk of sudden cardiac death with beta-blocker therapy, in this specific group of patients.

Entities:  

Year:  1999        PMID: 10754584     DOI: 10.1590/s0066-782x1999000900005

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  2 in total

1.  Beat-to-beat QT interval variability is primarily affected by the autonomic nervous system.

Authors:  Takanao Mine; Hiroki Shimizu; Kenji Hiromoto; Yoshio Furukawa; Tetsuzou Kanemori; Hiroaki Nakamura; Tohru Masuyama; Mitsumasa Ohyanagi
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-07       Impact factor: 1.468

2.  QT intervals and QT dispersion determined from a 12-lead 24-hour Holter recording in patients with coronary artery disease and patients with heart failure.

Authors:  Stig Hansen; Verner Rasmussen; Christian Torp-Pedersen; Gorm Boje Jensen
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-01       Impact factor: 1.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.